Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eimc.2016.08.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy.
Sci Rep
December 2024
American University of Beirut, Cairo Street, Riad El Solh, PO Box 11-0236/11D, Beirut, 1107 2020, Lebanon.
Febrile neutropenia is a major complication in patients with acute leukemia or those undergoing hematopoietic stem cell transplantation (HSCT). Understanding patient characteristics and susceptibility patterns in febrile neutropenia is essential for appropriate antimicrobial therapy. First-line agents should have Pseudomonas aeruginosa coverage, but with the increase in multi-drug resistant organisms, ceftazidime-avibactam has emerged as a new therapeutic option.
View Article and Find Full Text PDFCefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection.
Infect Drug Resist
November 2024
Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland.
Background: MDR/XDR constitutes a difficult to treat bacteria in a number of infections as there are few therapeutic options. Promising drugs in such cases can be cefiderocol, aztreonam and ceftazidime/avibactam or meropenem/vaborbactam.
Case Presentation: A 72-year-old female patient with sepsis caused by KP NDM, OXA 48 was admitted to the Intensive Care Unit, immediately after an emergency graftectomy (of a recently transplanted kidney) complicated with bleeding.
A Novel Variant of KPC-179 Conferring Ceftazidime-Avibactam Resistance in a Carbapenem-Resistant Isolate.
Infect Drug Resist
November 2024
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Objective: Ceftazidime-avibactam (CZA) is a novel -lactam/-lactamase inhibitor with activity against carbapenem-resistant (CRKP) that produce carbapenemase (KPC). In this study, we report the first cases of CZA resistance to develop during treatment of CRKP infections and identify the resistance mechanism.
Methods: APB/EDTA and NG-Test CARBA5 were used to detect the production of carbapenemase, whole-genome sequencing (WGS) and conjugation experiment were used to identify potential resistance mechanisms of CZA-susceptible (HX1032) and -resistant (HX1192) isolates.
Analysis of the virulence of a lethal, carbapenem-resistant hypervirulent KPC-33-producing Klebsiella pneumoniae: Emergence of ST11-KL64 hv-CRKP in ICU.
Microb Pathog
January 2025
Department of Clinical Laboratory, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, China. Electronic address:
Objective: Hypervirulent and carbapenem-resistant Klebsiella pneumoniae (hv-CRKP) poses a serious threat to public health. Here, we analyse a case of systemic infection caused by a hv-CRKP, which ultimately led to the patient's death from sepsis. And a total of 30 CRKPs were analyzed to elucidate the molecular epidemiological features of CRKPs in the hospital, and to provide a basis for clinical anti-infective therapy.
View Article and Find Full Text PDFIdentification of bla in Klebsiella pneumoniae associated with ceftazidime-avibactam resistance and the translocation & truncation of resistant genes mediated by IS26.
Int J Antimicrob Agents
January 2025
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China. Electronic address:
Objectives: In this study, we discovered bla in ceftazidime-avibactam resistant clinical isolates of K. pneumoniae from a patient with multiple comorbidities and investigated the resistance & transfer mechanism of bla.
Methods: K.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!